对于BCG不响应的非肌肉侵入性膀癌的肠道化疗组合治疗
Paolo Zaurito1,2, Pietro Scilipoti1,2, Francesco Montorsi1,2
1Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele.
Current opinion in urology
|July 15, 2025
概括
肠道化疗组合在膀癌患者中表现有前途,这些患者对Bacillus Calmette-Guérin (BCG) 没有反应. 吉米西塔加多塞塔克塞尔提供了良好的短期效果,目前正在研究用于膀节约疗法的多药疗法.
科学领域:
- 在瘤学瘤学.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
背景情况:
- 非肌肉侵入性膀癌 (NMIBC) 不对Bacillus Calmette-Guérin (BCG) 治疗有反应,这是一个临床挑战.
- 激进囊切除术 (RC) 是标准的治疗方法,但膀节省疗法 (BST) 的需求越来越大.
研究的目的:
- 审查BCG不响应 (U-BCG) NMIBC患者的静脉内化疗组合治疗的疗效和安全性.
- 评估对RC的替代疗法的最新证据.
主要方法:
- 对U-BCG NMIBC的静脉内化学疗法组合的最新文献进行系统审查.
- 分析疗效 (无复发存活率,无进展存活率,无囊切除存活率) 和安全性 (不良事件).
主要成果:
- 静脉内注射格美西他加多塞塔塞尔在回顾性系列中显示出有希望的疗效:2年无复发存活率 (37-62%) 和无进展存活率 (70-95%).
- 对于gemcitabine/docetaxel的3-5级不良事件范围在3-8%之间.
- 一个前性试验中,对gemcitabine,cabazitaxel和cisplatin的使用表明,无囊切除术的1年生存率为97%,没有严重的不良事件.
结论:
- 静脉内化学疗法组合证明了U-BCG NMIBC的良好的短期疗效和耐受性.
- 杰姆西塔宾/多塞塔克塞尔是一种常见的研究组合,对三重药物疗法有兴趣.
- 未来研究对于验证这些膀节省疗法作为激进囊切除术的替代品至关重要.
相关概念视频
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Tumor Immunotherapy
664
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
664
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Urinary Tract Calculi III: Medical Management
27
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
27
Cancer Vaccines
517
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
517
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K


